Background/Aims Hepatocellular carcinoma (HCC) is the most common liver cancer with high mortality rate in patients suffering from liver diseases. The drug of choice used in advanced-stage of HCC is sorafenib. However, adaptive resistance has been observed in HCC patients undergoing long-term sorafenib treatment, lowering its effectiveness. Hence, it is important to overcome drug resistance to improve overall management of HCC. Here, we have identified a candidate biomarker for sorafenib resistance in a HCC model cell line, HepG2.
Methods Initially, comparative proteomic profiling of parental HepG2 [HepG2 (P)] and sorafenib-resistant HepG2 [HepG2 (R)] cells was performed via MALDI (matrix-assisted laser desorption/ionization) which revealed the deregulation of vimentin in HepG2 (R) cells. Gene and protein level expression of vimentin was also observed through quantitative real-time polymerase chain reaction (qRT PCR) and fluorescence-activated cell sorting (FACS), respectively. Furthermore, withaferin A was used to study regulation of vimentin expression and its significance in sorafenib resistance.
Results Both gene and protein level of vimentin expression was found to be downregulated in HepG2 (R) in comparison to HepG2 (P). Interestingly, the study demonstrated that withaferin A further lowered the expression of vimentin in HepG2 (R) cells in a dose-dependent manner. Also, inhibition of vimentin lowered ABCG2 expression and decreased cell viability in parental as well as sorafenib resistant HepG2 cells.
Conclusions Hence, our study for the first time highlighted the probable therapeutic potential of vimentin in sorafenib resistant HepG2, a HCC model cell line.
Citations
Citations to this article as recorded by
CCDC137 affects sorafenib resistance in hepatocellular carcinoma cells by activating the AKT/mTOR signaling pathway Hanchuan Tao, Yu Wang, Fang Wang, Xingchi Hu, Cheng Wang Clinical and Translational Oncology.2026; 28(7): 2803. CrossRef
Withaferin A: Mechanisms of action, therapeutic efficacy, and clinical potential in gastrointestinal cancer treatment: a comprehensive review Ritu Chauhan, Suresh Babu Kondaveeti, Neelesh Babu, Vinay Mohan Pathak, Damandeep Kaur, Hardeep Singh Tuli, Anuj Ranjan, Naveen Chandra Joshi, Laurent Dufossé, Abhishek Chauhan Phytomedicine Plus.2026; 6(2): 100974. CrossRef
Targeting the Vim–PGI2 Pathway Enhances CD8+ T Cell‐Mediated Antitumor Immunity in Breast Cancer Hong Quan, Lujing Shao, Qi Li, Chunyan Dong, Peipei Gong Human Mutation.2026;[Epub] CrossRef
Combined downregulation of TGF-β1 and GRP78 is responsible for overcoming acquired sorafenib resistance, which is initiated by rewiring the cell surface CD44-GRP78-IGF-1R signaling circuit Shengji Li, Geun-Hyeok Oh, Jeong A. Hong, Soojin Choi, Minseo Kim, Hyeji Kwon, Seung-Kyun Ko, Sun Jun Park, Hee Kyung Kim, Hye Jin Choi, Jae J. Song Cancer Gene Therapy.2025; 32(8): 884. CrossRef
Enhanced combinatorial analysis of tumor cell-ECM interactions using design-of-experiment optimized microarrays Hannah R C Kimmel, Allison L Paxhia, Zahra Adamji, Gregory H Underhill Biofabrication.2025; 17(4): 045005. CrossRef
Withanolides: Promising candidates for cancer therapy Qiang Zhang, YongKang Yuan, Shijie Cao, Ning Kang, Feng Qiu Phytotherapy Research.2024; 38(2): 1104. CrossRef
Cytoskeletal gene alterations linked to sorafenib resistance in hepatocellular carcinoma Hong Xiao, Hangyu Chen, Lei Zhang, Maimaitiyasen Duolikun, Baixin Zhen, Subinuer Kuerban, Xuehui Li, Yuxi Wang, Long Chen, Jian Lin World Journal of Surgical Oncology.2024;[Epub] CrossRef
Comprehensive characterization of differential glycation in hepatocellular carcinoma using tissue proteomics with stable isotopic labeling Shanshan Qin, Ke Gao, Zhixin Tian Analytical and Bioanalytical Chemistry.2024; 416(20): 4531. CrossRef
Advances in hepatocellular carcinoma drug resistance models Yien Xiang, Jun Wu, Hanjiao Qin Frontiers in Medicine.2024;[Epub] CrossRef
Bacterial metabolite butyrate in modulating sorafenib-targeted microRNAs to curtail its resistance in hepatocellular carcinoma Mukesh Kumar, Ramanpreet Kaur, Shruthi Kanthaje, Radha K. Dhiman, Anuradha Chakraborti Journal of Cancer Research and Clinical Oncology.2023; 149(9): 5823. CrossRef
Withaferin A: A Dietary Supplement with Promising Potential as an Anti-Tumor Therapeutic for Cancer Treatment - Pharmacology and Mechanisms Zhichao Xing, Anping Su, Li Mi, Yujie Zhang, Ting He, Yuxuan Qiu, Tao Wei, Zhihui Li, Jingqiang Zhu, Wenshuang Wu Drug Design, Development and Therapy.2023; Volume 17: 2909. CrossRef
Molecular targets and mechanisms of anti-cancer effects of withanolides Zhiruo Zhang, Yueying Yang, Yang Xu, Yang Liu, Hua Li, Lixia Chen Chemico-Biological Interactions.2023; 384: 110698. CrossRef
Label-Free Quantitative Proteomics Analysis of the Sorafenib Resistance in HepG2 Cells Zi-Xuan Wang, Hong-Wei Chu, Kai-Guang Yang, Bao-Feng Zhao, Zhen Liang, Li-Hua Zhang, Yu-Kui Zhang Journal of Analysis and Testing.2022; 6(3): 308. CrossRef
Role of ATP-binding Cassette Transporters in Sorafenib Therapy for Hepatocellular
Carcinoma: An Overview Maria Manuela Estevinho, Carlos Fernandes, João Carlos Silva, Ana Catarina Gomes, Edgar Afecto, João Correia, João Carvalho Current Drug Targets.2022; 23(1): 21. CrossRef
Feedback regulation of antioxidant transcription factor NFE2L1 and immunostimulatory factor 41BBL mediates the crosstalk between oxidative stress and tumor immunity Lu Qiu, Haoming Ning, Yaqian Zhu, Qiufang Yang, Lulu Liu, Lei Luo, Yanfeng Gao, Yadi Xing Molecular Immunology.2022; 141: 265. CrossRef
miR-23b-3p Modulating Cytoprotective Autophagy and Glutamine Addiction in Sorafenib Resistant HepG2, a Hepatocellular Carcinoma Cell Line Ramanpreet Kaur, Shruthi Kanthaje, Sunil Taneja, Radha K. Dhiman, Anuradha Chakraborti Genes.2022; 13(8): 1375. CrossRef
MicroRNA-138-1-3p sensitizes sorafenib to hepatocellular carcinoma by targeting PAK5 mediated β-catenin/ABCB1 signaling pathway Tong-tong Li, Jie Mou, Yao-jie Pan, Fu-chun Huo, Wen-qi Du, Jia Liang, Yang Wang, Lan-sheng Zhang, Dong-sheng Pei Journal of Biomedical Science.2021;[Epub] CrossRef
Exacerbation of Liver Tumor Metastasis in twist1a+/xmrk+ Double Transgenic Zebrafish following Lipopolysaccharide or Dextran Sulphate Sodium Exposure Jeng-Wei Lu, Yuxi Sun, Liang-In Lin, Dong Liu, Zhiyuan Gong Pharmaceuticals.2021; 14(9): 867. CrossRef
Circulating Tumor Cells Expressing Krüppel-Like Factor 8 and Vimentin as Predictors of Poor Prognosis in Pancreatic Cancer Patients Peng Zhu, Hui-Ying Liu, Fu-Chen Liu, Fang-Ming Gu, Sheng-Xian Yuan, Jian Huang, Ze-Ya Pan, Wei-Jun Wang Cancer Control.2021;[Epub] CrossRef
RETRACTED ARTICLE: The miR-30a-5p/CLCF1 axis regulates sorafenib resistance and aerobic glycolysis in hepatocellular carcinoma Zhongqiang Zhang, Xiao Tan, Jing Luo, Hongliang Yao, Zhongzhou Si, Jing-Shan Tong Cell Death & Disease.2020;[Epub] CrossRef
Reactive oxygen species-induced activation of Yes-associated protein-1 through the c-Myc pathway is a therapeutic target in hepatocellular carcinoma Yuri Cho, Min Ji Park, Koeun Kim, Sun Woong Kim, Wonjin Kim, Sooyeon Oh, Joo Ho Lee World Journal of Gastroenterology.2020; 26(42): 6599. CrossRef
Iron elevates mesenchymal and metastatic biomarkers in HepG2 cells Kosha J. Mehta, Paul A. Sharp Scientific Reports.2020;[Epub] CrossRef
First
Prev
